Syndeio Biosciences

The company is at the forefront of developing drug candidates that leverage a unique synapse pharmacology platform to address central nervous system (CNS) disorders. By focusing on synaptic health, the company targets diseases characterized by synaptic weakening, such as depression and schizophrenia, which affect over a billion people globally. The business model revolves around creating therapies that trigger lasting biological changes with a single drug dose, thereby strengthening neuron connections. This approach is not only rapid-acting but also aims to be safer and more effective than traditional methods. The company's proprietary platform, developed from the Standard University laboratory of Nobel laureate Thomas C. M.D., integrates molecular, functional, and behavioral insights to optimize synapse biology. Currently, a Phase 2a trial in collaboration with the University of Pittsburgh is underway, evaluating the potential of apimostinel, an NMDAR positive allosteric modulator, paired with digital therapy for enhanced outcomes. The company generates revenue through the development and potential commercialization of these transformative therapies, with a focus on establishing a best-in-class safety and efficacy profile for acute depression treatment. Keywords: synapse, pharmacology, CNS disorders, depression, schizophrenia, neuron connections, apimostinel, NMDAR, digital therapy, clinical trials.